Le Lézard
Classified in: Health
Subjects: ACC, SHM

Bulletin from Bactiguard Holding AB's (publ) Annual General Meeting


STOCKHOLM, May 5, 2023 /PRNewswire/ --

At Bactiguard Holding AB's (publ) Annual General Meeting (AGM) on 5 May 2023, the following resolutions were made:

The AGM adopted the income statements and balance sheets for 2022 and decided that no dividend for the financial year 2022 will be paid. Retained earnings and the company's result for the year will be carried forward.

The Board of Directors and CEO were discharged from liability for their administration of the company for the financial year 2022.

The AGM resolved that the remuneration until the next AGM shall be paid in an amount of SEK 750?000 respectively to the Chairman of the Board and the deputy Chairman and SEK 400?000 to each of the other Directors. No additional remuneration shall be paid for committee work. 

Christian Kinch, Anna Martiling, Magdalena Persson, Jan Ståhlberg and Thomas von Koch were re-elected as board members and Dr Rick Kuntz was elected as new member of the Board. Thomas von Koch was re-elected Chairman of the Board and Christian Kinch was re-elected deputy Chairman of the Board.

Deloitte AB was re-elected by the AGM as auditors for the period until the close of the next AGM and it was resolved that remuneration to the auditors shall be paid according to approved invoices.

The AGM adopted the remuneration report, proposed by the Board.

The AGM resolved, in accordance with the Board's proposal, on the authorization for the Board to decide on a new issue of shares, warrants and / or convertibles.

For more information, please contact:

Carin Jakobson, CFO, mobile: +46 709 651 665
Bactiguard press office +46 8 440 58 80 [email protected]

The following files are available for download:

https://mb.cision.com/Public/9686/3765039/98cbfb2865aeb684.pdf

230505 Bulletin from Bactiguard Holding ABs publ AGM eng

 

SOURCE Bactiguard Holding AB (publ)


These press releases may also interest you

at 05:11
Hyundai Bioscience announced on April 25th that its clinical development plan of oral "Niclosamide Metabolic Anticancer Drug" targeting cancer patients with intractable cancer caused by p53 gene mutations. Mutations in the p53 gene occur in almost...

at 04:31
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CHINA, HONG KONG, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR IN ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR...

at 04:30
The Balance RehabClinic, renowned for its luxury mental health and addiction services, proudly announces its expansion into The Balance Healthcare Group: a collection of premium mental health solutions tailored for affluent individuals. These new...

at 03:47
Zest Dental Solutions, a global leader in innovative dental solutions proudly announces a strategic partnership with The Pathway. Founded by Justin Moody, DDS and based in Arizona, The Pathway is a continuing education program that teaches dentists...

at 03:34
Medivir AB (STO: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that its selective cathepsin K inhibitor, MIV-711, has been granted Rare Pediatric Disease...

at 03:16
First quarter Net sales reached SEK 9.4 (13.0) million.The operating result totaled SEK -18.4 (-14.4) million.Earnings per share, basic and diluted, were SEK -0.11 (-0.09).Cash flow from operating activities totaled SEK -7.3 (-12.2) million.CEO...



News published on and distributed by: